Genetic Analysis of Clopidogrel Resistance

Platelets have a crucial role in homeostasis and thrombosis. Their haemostatic role is to prevent from bleeding after activation in the platelet aggregation pathway. In pathologic cases, they contribute to atherothrombosis. Antiplatelet drugs inhibit platelet aggregation so they are used successfully in treatment courses. Clopidogrel, an antiplatelet drug, is an ADP analogue. It inhibits ADP coupling with its receptor and prevents atherothrombosis. Despite its great success, some patients do not display an adequate antiplatelet response due to genetic resistance. Genetic investigations have displayed CYP2C19 polymorphism as the most prevalence factor of genetic resistance. Use of higher doses of Clopidogrel, combined antiplatelet therapies or new potent drugs is a potential alternative strategy.